Modality
Bispecific Ab
MOA
PRMT5i
Target
TIM-3
Pathway
STING
Cervical CaMCCMyelofibrosis
Development Pipeline
Preclinical
~Dec 2013
→ ~Mar 2015
Phase 1
~Jun 2015
→ ~Sep 2016
Phase 2
~Dec 2016
→ ~Mar 2018
Phase 3
~Jun 2018
→ ~Sep 2019
NDA/BLA
Dec 2019
→ Oct 2030
NDA/BLACurrent
NCT03469795
753 pts·Myelofibrosis
2019-12→2030-10·Terminated
753 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-10-204.6y awayPh3 Readout· Myelofibrosis
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2030-10-20 · 4.6y away
Myelofibrosis
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03469795 | NDA/BLA | Myelofibrosis | Terminated | 753 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 |